SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Marawan Ahmed, Feng Wang, Aviad Levin, Connie Le, Yomna Eltayebi, Michael Houghton, Lorne Tyrrell, Khaled Barakat, Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA, Drug Discovery Today, 2015,

    CrossRef

  2. 2
    Mahboubeh Rostami, Ahmad R. Khosropour, Valiollah Mirkhani, Iraj Mohammadpoor-Baltork, Majid Moghadam, Shahram Tangestaninejad, [C6(MIm)2]2W10O32 catalyzed efficient one-pot pseudo-four component synthesis of AT-130 analogues under microwave irradiations, Journal of the Iranian Chemical Society, 2014, 11, 5, 1493

    CrossRef

  3. 3
    W. P. Brouwer, M. J. Sonneveld, F. Tabak, K. Simon, Y. Cakaloglu, U. S. Akarca, S. Zeuzem, P. Ferenci, J. E. Heathcote, R. J. Knegt, A. Boonstra, B. E. Hansen, H. L. A. Janssen, Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2014, 40, 7
  4. 4
    M. J. Sonneveld, R. Zoutendijk, H. J. Flink, L. Zwang, B. E. Hansen, H. L. A. Janssen, Close Monitoring of Hepatitis B Surface Antigen Levels Helps Classify Flares During Peginterferon Therapy and Predicts Treatment Response, Clinical Infectious Diseases, 2013, 56, 1, 100

    CrossRef

  5. 5
    Mehlika Toy, Cost-effectiveness of viral hepatitis B & C treatment, Best Practice & Research Clinical Gastroenterology, 2013, 27, 6, 973

    CrossRef

  6. You have free access to this content6
    L. Boglione, A. D'Avolio, G. Cariti, M. G. Milia, M. Simiele, A. Nicolò, V. Ghisetti, G. Di Perri, Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes, Journal of Viral Hepatitis, 2013, 20, 4
  7. 7
    Milan J. Sonneveld, Pauline Arends, Andre Boonstra, Bettina E. Hansen, Harry L.A. Janssen, Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B, Journal of Hepatology, 2013, 58, 5, 898

    CrossRef

  8. 8
    Juan Lv, Qinglong Jin, Haibo Sun, Xiumei Chi, Xiaoli Hu, Hongqing Yan, Yu Pan, Weihua Xiao, Zhigang Tian, Jinlin Hou, Damo Xu, Zhengkun Tu, Junqi Niu, Antiviral Treatment Alters the Frequency of Activating and Inhibitory Receptor-Expressing Natural Killer Cells in Chronic Hepatitis B Virus Infected Patients, Mediators of Inflammation, 2012, 2012, 1

    CrossRef

  9. 9
    Tony Andreani, HBV-carriers: When is monitoring and surveillance sufficient? (point of view), Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 12, 813

    CrossRef

  10. 10
    Y. Liang, J. Jiang, M. Su, Z. Liu, W. Guo, X. Huang, R. Xie, S. Ge, J. Hu, Z. Jiang, M. Zhu, V. W.-S. Wong, H. L.-Y. Chan, Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy, Alimentary Pharmacology & Therapeutics, 2011, 34, 3
  11. 11
    Chih-Lin Lin, Jia-Horng Kao, Recent advances in the treatment of chronic hepatitis B, Expert Opinion on Pharmacotherapy, 2011, 12, 13, 2025

    CrossRef

  12. 12
    A. Messori, F. Del Santo, D. Maratea, S. Trippoli, Single-drug treatments for chronic hepatitis B: summarising current information by network meta-analysis, Alimentary Pharmacology & Therapeutics, 2011, 34, 1